International Journal of Clinical Practice

Research Article

Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis

Table 1

Characteristics of the selected articles and risk of bias assessment.
StudyStudy periodCountryType of studynAge+EBV, nSex (% male)TreatmentsMV, n+EBV mortality, nD-dimer(mg/L)NOS
Xie et al. [1]Jan–Mar 20ChinaRetro128621758.81–2 mg/kg intravenous glucocorticoids for 5–7 days in critically ill patientsNA54.26 vs 6.677
Meng et al. [12]Jan–Mar 20ChinaRetro217545537(i) Ganciclovir
(ii) Glucocorticoids (different study design to address mortality with or without ganciclovir treatment)		NA120.56 vs 0.97
Naendrup et al. [13]Mar 20-Mar 21GermanyRetro117601989(i) Dexamethasone (6 mg/d) as part of the current COVID-19 treatment protocol
(ii) Rituximab		NA12NA7
Saade et al. [14]Feb–May 20FranceRetro100605875(i) Dexamethasone
(ii) Lopinavir/ritonavir
(iii) Eculizumat
(iv) Tocilizumab		3718NA7
 = ; MV = mechanical ventilation; NA=not applicable; n = number; d = day; NOS = Newcastle–Ottawa Scale.